Literature DB >> 1684323

Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.

W Becker1, J Marienhagen, R Scheubel, A Saptogino, W H Bakker, W A Breeman, F Wolf.   

Abstract

Tyr-3-Octreotide is a synthetic derivative of somatostatin and a somatostatin-receptor analogue. The iodine-123-labelled compound localizes somatostatin-receptor-positive tumours. In this paper two patients are reported in whom somatostatin receptors were demonstrated in vitro. In a 60-year-old female with an islet cell carcinoma of the pancreas, multiple liver metastases and previously unrecognized bone metastases in the right acetabulum could be diagnosed as the reason for a persistent hypoglycaemia. In a 60-year-old male an islet cell carcinoma of the pancreas was localized with 123I-Tyr-3-octreotide. The somatostatin receptors were demonstrated in vitro and the tumour was successfully treated with somatostatin. These studies demonstrate that 123I-Tyr-3-octreotide offers the possibility of localizing somatostatin-receptor-positive tumours and their metastases. Moreover the method makes it possible to determine the receptor status of a tumour in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684323     DOI: 10.1007/bf02258458

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors.

Authors:  J C Reubi; W H Häcki; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1987-12       Impact factor: 5.958

2.  Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

3.  Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases.

Authors:  P Stefanini; M Carboni; N Patrassi; A Basoli
Journal:  Surgery       Date:  1974-04       Impact factor: 3.982

4.  Somatostatin-receptor imaging in the localization of endocrine tumors.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

5.  Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.

Authors:  S W Lamberts; L J Hofland; P M van Koetsveld; J C Reubi; H A Bruining; W H Bakker; E P Krenning
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

Review 6.  Distribution of somatostatin receptors in normal and tumor tissue.

Authors:  J C Reubi; L Kvols; E Krenning; S W Lamberts
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

7.  Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

Authors:  E P Krenning; W H Bakker; W A Breeman; J W Koper; P P Kooij; L Ausema; J S Lameris; J C Reubi; S W Lamberts
Journal:  Lancet       Date:  1989-02-04       Impact factor: 79.321

8.  Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

Authors:  W H Bakker; E P Krenning; W A Breeman; J W Koper; P P Kooij; J C Reubi; J G Klijn; T J Visser; R Docter; S W Lamberts
Journal:  J Nucl Med       Date:  1990-09       Impact factor: 10.057

Review 9.  Glucagonomas, VIPomas and somatostatinomas.

Authors:  S R Bloom; J M Polak
Journal:  Clin Endocrinol Metab       Date:  1980-07
  9 in total
  3 in total

1.  A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.

Authors:  W A Breeman; L J Hofland; M van der Pluijm; P M van Koetsveld; M de Jong; B Setyono-Han; W H Bakker; D J Kwekkeboom; T J Visser; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1994-04

2.  Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.

Authors:  W A Breeman; L J Hofland; W H Bakker; M van der Pluijm; P M van Koetsveld; M de Jong; B Setyono-Han; D J Kwekkeboom; T J Visser; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1993-11

Review 3.  Neuroendocrine metastases of the liver.

Authors:  I Ihse; B Persson; S Tibblin
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.